BLACK DIAMOND THERAPEUTICS, INC. (BDTX) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 28.13M USD | Research and Development Expense |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 6.11M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -51.90M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $28.13M | (m) | $6.11M | $-51.90M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $30.05M | (m) | $6.38M | $-53.27M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $33.56M | (m) | $6.63M | $12.52M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $39.56M | (m) | $6.85M | $11.86M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $45.04M | (m) | $7.11M | $4.71M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $48.27M | (m) | $10.61M | $-4.00M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $51.31M | (m) | $10.63M | $-78.78M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $54.30M | (m) | $10.53M | $-81.36M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $57.54M | (m) | $11.29M | $-87.24M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $58.14M | (m) | $8.65M | $-85.14M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $59.35M | (m) | $9.60M | $-86.46M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $58.67M | (m) | $10.97M | $-87.46M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $58.36M | (m) | $10.89M | $-85.57M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $61.40M | (m) | $11.49M | $-88.71M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $64.44M | (m) | $12.20M | $-92.83M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $69.49M | (m) | $12.67M | $-97.06M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $81.27M | (m) | $13.01M | $-110.30M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $91.80M | (m) | $14.32M | $-121.84M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $96.83M | (m) | $14.04M | $-126.87M | $0.00 | (m) | (m) | (m) | Reported |
| 2021-09-30 | $94.92M | (m) | $13.13M | $-123.97M | $0.00 | (m) | (m) | (m) | Reported |
| 2021-06-30 | $80.22M | (m) | $12.12M | $-107.09M | $0.00 | (m) | (m) | (m) | Reported |
| 2021-03-31 | $63.67M | (m) | $8.98M | $-87.40M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $48.21M | $0.00 | $7.76M | $-69.57M | $1.00K | (m) | (m) | -69570.00× | Reported |
| 2020-09-30 | $37.91M | (m) | $7.80M | $-56.73M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $30.62M | (m) | $6.66M | $-46.40M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $26.09M | (m) | $5.43M | $-38.37M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $21.75M | $0.00 | $3.64M | $-29.33M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $0.00 | (m) | $-22.03M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $0.00 | (m) | $-16.23M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $0.00 | (m) | $-11.14M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $6.95M | $0.00 | $64.00K | $-8.90M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |